New daily pill shows promise for tough cancers

NCT ID NCT07321574

Recruiting now Disease control Sponsor: Shanghai AB PharmaTech Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it is. The study is for those who have tried other treatments without success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer esophageal cancer neoplasm renal cell carcinoma small cell lung carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS SCLC, EXTENSIVE STAGE

Contacts and locations

Locations

Liaocheng Second People's Hospital
RECRUITING

Liaocheng, Shandong, China
Neijiang First People's Hospital
RECRUITING

Neijiang, Sichuan, China
Shanghai East Hospital
RECRUITING

Shanghai, China
Shanghai Pulmonary Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Shanxi Bethune Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, China
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITING

Luoyang, Henan, China
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanyang Medical College
NOT_YET_RECRUITING

Nanyang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.